References
- Akabane T, Tanaka K, Irie M, et al. (2011). Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372–84
- Argikar UA, Potter PM, Hutzler JM, et al. (2016). Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J 18:1391–405
- Asano T, Suzuki T, Tsuchiya M, et al. (1989). Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 98:1091–100
- Beedham C, Bruce SE, Critchley DJ, et al. (1987). Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307–10
- Diamond S, Boer J, Maduskuie TP, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–85
- Fuchs P, Haefeli WE, Ledermann HR, et al. (1999). Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol 54:869–76
- Garattini E, Mendel R, Romao MJ, et al. (2008). Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15–32
- Garattini E, Terao M. (2012). The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487–503
- Hinderling PH, Karara AH, Tao B, et al. (2007). Systemic availability of the active metabolite hydroxyfasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol 47:19–25
- Kitamura S, Tatsumi K. (1984). Involvement of liver aldehyde oxidase in the reduction of nicotinamide N-oxide. Biochem Biophys Res Commun 120:602–6
- Kitamura S, Sugihara K, Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83–98
- Obach RS. (2004). Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89–97
- Panoutsopoulos GI, Beedham C. (2004). Kinetics and specificity of guinea pig liver aldehyde oxidase and bovine milk xanthine oxidase towards substituted benzaldehydes. Acta Biochim Pol 51:649–63
- Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441–60
- Sanoh S, Horiguchi A, Sugihara K, et al. (2012). Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 40:322–8
- Satoh S, Takayasu M, Kawasaki K, et al. (2012). Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. J Pharmacol Sci 118:92–8
- Shibuya M, Suzuki Y, Sugita K, et al. (1992). Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:571–7
- Stell JG, Wheelhouse RT, Wright CW. (2012). Metabolism of cryptolepine and 2-fluorocryptolepine by aldehyde oxidase. J Pharm Pharmacol 64:237–43
- Terao M, Romão MJ, Leimkühler S, et al. (2016). Structure and function of mammalian aldehyde oxidases. Arch Toxicol 90:753–80
- Zientek M, Jiang Y, Youdim K, et al. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–7